Human Antibody Discovery from MPN Patient B Cells v1.0

  • Research type

    Research Study

  • Full title

    Human Antibody Discovery from Myeloproliferative Neoplasm (MPN) Patient B Cells Using Single B Cell Screening Technology.

  • IRAS ID

    373826

  • Contact name

    Manjunath Hegde

  • Contact email

    mhegde@fjbio.com

  • Sponsor organisation

    IONTAS LTD

  • Clinicaltrials.gov Identifier

    373826, IRAS Project ID

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    Myeloproliferative neoplasms (MPNs) are blood cancers affecting the bone marrow's ability to produce healthy blood cells. Specific protein dysregulation is found in many MPN patients and drive the disease. The aim of this study is to find human antibodies, which are naturally produced proteins by the immune system, that can recognise and bind specifically to cells carrying these dysregulated proteins. If successful, these antibodies could form the basis of new treatments for MPN that spare healthy cells.

    Patients with MPN may produce antibodies targeting the disease-associated changes in their own cells as part of their natural immune response. This study will use stored blood samples (peripheral blood mononuclear cells and serum) donated by MPN patients carrying this genetic change, obtained with appropriate consent from specialist commercial biobanks in the United States. No patients will be directly recruited or attend any clinical appointments as part of this study. All work will be carried out in the laboratory at IONTAS Ltd in Cambridge, UK.

    The laboratory work involves three stages: (1) screening patient blood samples for evidence of an immune response targeting the disease-associated cell surface change; (2) isolating and stimulating the B cells (immune cells that make antibodies) from the most promising donors; and (3) using a single-cell analysis platform to identify individual B cells producing the desired antibodies and recover their sequences.

    The study is funded by a US-based biopharmaceutical company and will be conducted at IONTAS Ltd, Cambridge. Results will not be fed back to individual donors as samples are anonymised.

  • REC name

    East Midlands - Nottingham 1 Research Ethics Committee

  • REC reference

    26/EM/0173

  • Date of REC Opinion

    4 Aug 2026

  • REC opinion

    Favourable Opinion